2023 World Conference on Lung Cancer (Posters)-EP13.03. Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study

EP13.03. Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study - PDF(Abstract)

Back to course

Pdf Summary

This study focused on the correlation between immune-related adverse events (irAEs) and the efficacy of PD-1/PD-L1 inhibitors in the treatment of small cell lung cancer (SCLC) in China. The retrospective cohort study included 219 SCLC patients who received these inhibitors between January 2008 and June 2022. The objective response rate, disease control rate, progression-free survival, and overall survival were analyzed as endpoints of clinical efficacy.<br /><br />Results showed that 51% of the patients experienced irAEs, with the majority experiencing grade 1 to 2 irAEs. The most common irAEs were endocrine system toxicity, skin reactions, and immune pneumonia. Patients in the irAE group had a longer median progression-free survival (8.2 months vs 4.4 months) and overall survival (27.0 months vs 19.6 months) compared to those in the no-irAE group.<br /><br />Thyroid dysfunction was identified as the most powerful indicator for improved progression-free survival and overall survival. The occurrence of irAEs was associated with a significant improvement in progression-free survival but not in overall survival in the multivariate analysis. Patients who developed multi-system irAEs had a longer progression-free survival and overall survival compared to those who developed single-system irAEs.<br /><br />The findings suggest that the presence of irAEs predicts superior clinical benefit in SCLC patients receiving PD-1/PD-L1 inhibitors. Furthermore, patients who develop multi-system irAEs may have improved survival compared to those who develop single-system irAEs. These results highlight the importance of monitoring and managing irAEs in SCLC patients treated with PD-1/PD-L1 inhibitors.

Asset Subtitle

Yuping Sun

Meta Tag

Speaker Yuping Sun

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

immune-related adverse events

efficacy

PD-1/PD-L1 inhibitors

small cell lung cancer

retrospective cohort study

progression-free survival

overall survival

endocrine system toxicity

skin reactions

thyroid dysfunction